P75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

ABSTRACT: p75 neurotrophin receptor (p75^NTR) signaling pathways substantially overlap with degenerative networks active in Alzheimer disease (AD). Modulation of p75^NTR with the first-in-class small molecule LM11A-31 mitigates amyloid-induced and pathological tau-induced synaptic loss in preclinical models. Here we conducted a 26-week randomized, placebo-controlled, double-blinded phase 2a safety and exploratory endpoint trial of LM11A-31 in 242 participants with mild to moderate AD with three arms: placebo, 200 mg LM11A-31 and 400 mg LM11A-31, administered twice daily by oral capsules. This trial met its primary endpoint of safety and tolerability. Within the prespecified secondary and exploratory outcome domains (structural magnetic resonance imaging, fluorodeoxyglucose positr

SUBMITTER: Shanks HRC 

PROVIDER: S-EPMC11186782 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature